Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.38 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15565954 | 1.00 | CYP2C9 (0.53) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL932966 | 1.00 | CYP2C9 (0.53) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL3230226 | 0.90 | CYP2C9 (0.58) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL31299649 | 0.86 | CYP2C9 (0.45) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL120745 | 0.84 | GLO1 (0.64) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL365557 | 0.84 | CYP2C9 (0.53) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL5902214 | 0.84 | GLO1 (0.64) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL120746 | 0.84 | GLO1 (0.64) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL18733161 | 0.82 | CYP2C9 (0.51) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 | |
| SCHEMBL5902803 | 0.82 | CYP2C9 (0.51) | CYP2C9NPSR1GLO1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290357-A | Heterocyclic compounds useful in the treatment of disease | 艾匹根生物技术有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-114644565-B | Synthesis method of key intermediate of imidazolinone compound | 江苏中旗科技股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-112424174-B | Heterocyclic compounds useful in the treatment of disease | 艾匹根生物技术有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-114644565-A | Synthesis method of key intermediate of imidazolone compound | 江苏中旗科技股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3807254-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | Epigen Biosciences, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3068785-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-26 | — | — | EP | disclosed |
| CN-105916855-B | Substituted 4, 5, 6, 7-tetrahydropyrazolo [1,5-a ] pyrazine derivatives as casein kinase 1D/E inhibitors | 百时美施贵宝公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105916856-B | Substituted 4,5,6,7- tetrahydro-pyrazoles as Casein kinase 1 D/E inhibitor simultaneously [1,5-A] pyrazines derivatives | 百时美施贵宝公司 | 2018-09-25 | — | — | CN | disclosed |
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-8263584-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2480546-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2451450-A1 | NEW INHIBITORS OF PROLINE RACEMASE ENZYMES | Institut Pasteur (FR) | 2012-05-16 | — | — | EP | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| WO-2011117264-A1 | N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDE DERIVATIVES AND THEIR USE AS PDE10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-8017604-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2011036127-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2011004323-A1 | NEW INHIBITORS OF PROLINE RACEMASE ENZYMES | INSTITUT PASTEUR (FR) | 2011-01-13 | — | — | WO | disclosed |
| EP-2272510-A1 | Inhibitors of the proline racemase of trypanosoma cruzi | Institut Pasteur (FR) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | PDE5A, PDE3B, PDE3A | CYP2C9 81/4885NPSR1 1343/4885GLO1 3760/4885 |
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | PDE10A, PDE4A, PDE3A | CYP2C9 251/4885NPSR1 538/4885GLO1 4202/4885 |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR2, LPAR4 | CYP2C9 3544/4885NPSR1 417/4885GLO1 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.